Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$305K Hold
10,708
– – 0.12% 77
2026
Q2
$258K Sell
10,708
-320
-3% -$8.37K 0.11% 83
2026
Q1
$310K Hold
11,028
– – 0.15% 72
2025
Q4
$275K Hold
11,028
– – 0.13% 78
2025
Q3
$281K Hold
11,028
– – 0.14% 75
2025
Q2
$267K Hold
11,028
– – 0.14% 67
2025
Q1
$279K Sell
11,028
-1,367
-11% -$35.8K 0.16% 62
2024
Q4
$329K Buy
12,395
+66
+0.5% +$1.79K 0.2% 60
2024
Q3
$357K Hold
12,329
– – 0.22% 57
2024
Q2
$345K Hold
12,329
– – 0.23% 55
2024
Q1
$342K Sell
12,329
-984
-7% -$27.3K 0.23% 56
2023
Q4
$383K Sell
13,313
-348
-3% -$10.5K 0.27% 50
2023
Q3
$453K Hold
13,661
– – 0.34% 45
2023
Q2
$501K Hold
13,661
– – 0.35% 45
2023
Q1
$557K Buy
13,661
+3
+0% +$130 0.4% 41
2022
Q4
$700K Buy
13,658
+264
+2% +$12.7K 0.53% 34
2022
Q3
$586K Hold
13,394
– – 0.66% 28
2022
Q2
$702K Hold
13,394
– – 0.75% 23
2022
Q1
$693K Hold
13,394
– – 0.65% 25
2021
Q4
$790K Hold
13,394
– – 0.67% 24
2021
Q3
$576K Sell
13,394
-300
-2% -$13.3K 0.53% 29
2021
Q2
$536K Buy
13,694
+300
+2% +$11.7K 0.49% 30
2021
Q1
$485K Sell
13,394
-364
-3% -$12.9K 0.48% 32
2020
Q4
$506K Buy
+13,758
New +$505K 0.41% 38

Other funds holding PFE

ADE LLC's PFE Position: Q3 2026 in Review

ADE LLC held its Pfizer (PFE) position steady in Q3 2026 at 10,708 shares worth $305K. The position accounts for 0.12% of the portfolio, ranked #77.

ADE LLC first reported a position in PFE in Q4 2020 and has held it in 24 quarters since. The position peaked at $790K in Q4 2021. 1,568 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • ADE LLC held 10,708 shares of Pfizer worth $305K as of Q3 2026.
  • ADE LLC left its Pfizer share count unchanged in Q3 2026.
  • Pfizer made up 0.12% of ADE LLC's portfolio in Q3 2026, its #77 holding.
  • ADE LLC first reported a position in Pfizer in Q4 2020 and has held it in 24 quarters since.
  • ADE LLC's Pfizer position peaked at $790K in Q4 2021.
  • 1,568 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on ADE LLC's 13F filing for Q3 2026, filed 29 Oct 2026.